Science & Enterprise subscription

Please share Science & Enterprise

RSS
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

NIH Grant Aims to Make Drugs Taste Better, Not Bitter

Dispensing pills

(Defense.gov)

14 September 2018. A new award from National Institutes of Health funds a study to identify components in taste bud cells that block bitter taste sensations encountered in some drugs and foods. The $271,000 Small Business Technology Transfer grant from National Institute on Deafness and Other Communication Disorders, part of NIH, was made to Monell Chemical Senses Center, a research institute in Philadelphia, and Discovery BioMed Inc., a drug discovery company in Birmingham, Alabama.

The project aims to find a mechanism for stopping the bitter taste that some people experience when taking food or medications. These bitter sensations can impede healthy eating habits and make it more difficult for some people, particularly children and older individuals, to take their prescribed drugs. Bitter taste sensations, says the Monell Center, probably evolved in humans as a way to protect against ingesting toxins. While adding sugar, artificial sweeteners, or salt can mask bitter tastes, those solutions are not always healthy choices for many people, such as those with diabetes or hypertension.

The one-year study plans to advance earlier research at Monell Center on the physiology of human taste bud cells, combined with Discovery BioMed’s work with high-throughput screening technologies using human tissue samples. Monell Center will establish cultures of cells in the lining of taste buds from donors who report bitter taste experiences, as well as collect genetic data indicating their heightened bitter-taste sensitivity. With those cultures, Discovery BioMed will create taste bud cell lines that grow indefinitely, then clone the bitter-taste sensitive cells to develop a technology for high-speed screening of molecules that block bitter sensation receptors. To prove the concept, the project includes testing the system with known and validated substances that activate bitter-taste sensations.

“Using human-derived taste cells to identify potential bitter blocking compounds is more likely to identify blockers that also work in human subjects than tests done in non-taste cells,” says Danielle Reed, associate director of the Monell Center, in a statement. “During this first phase of development, our goal is to establish the technical merit and feasibility of our approach so that we have a robust platform on which to discover, validate, and profile bitter taste antagonists moving forward.”

The award to Discovery BioMed and the Monell Center was made under NIH’s Small Business Technology Transfer or STTR grant program. STTR grants are funds set aside from the agency’s research budget for collaborations between small businesses and academic or not-for-profit research labs. In STTR and related Small Business Innovation Research, or SBIR grants awarded to small businesses alone, the first phase of a typical project establishes its technical and commercial feasibility, and if successful, can be extended in a second phase to develop the technology into working prototypes or for clinical trials.

More from Science & Enterprise:

*     *     *

Univ. Spin-Off Developing A.I.-Boosted Heart Monitor

Heartbeat graphic

(Maxpixel.net)

13 September 2018. A new enterprise in the U.K. is developing a wearable heart monitor that diagnoses irregular heart rhythms with artificial intelligence using cloud-based algorithms. The company, Cambridge Heartware, was founded in 2017 by medical and engineering researchers at University of Cambridge.

Cambridge Heartware’s product, known as Heartsense, is a system that monitors and analyzes heart rhythms and other vital signs for signs of atrial fibrillation, a disorder where the atria, or upper chambers of the heart, beat irregularly instead of the normal, smooth regular beats that move blood effectively through the blood stream. Because of these irregular heart rhythms, blood can pool in the atria and form clots. If a clot should break off and flow to the brain, it can cause a stroke. According to American Heart Association, 15 to 20 percent of people who have a stroke also have atrial fibrillation.

The university cites data showing more than 1 million people in the U.K. have atrial fibrillation, with more than 100,000 people suffering a stroke each year, resulting in some 23,000 deaths in the U.K. last year. The country’s National Health Service says it spends £2.5 billion ($US 4 billion) each year on treatment and care of stroke patients.

The current system used most often for day-to-day atrial fibrillation monitoring is the Holter monitor, a non-invasive device with 12 wires pasted on the torso, leading to a controller worn by the patient for an entire day. Data from the monitor are later downloaded to a separate system for analysis and interpretation.

The Heartsense system includes a wearable heart and vital signs monitor worn around the chest that measures heart rhythms like an electrocardiogram or ECG, but also core body temperature and oxygen levels in the blood. The ECG module in Heartsense measures heart rhythms at 3 points, but the entire monitoring hardware is packaged in a small waterproof plastic container that its developers say was ergonomically designed by colleagues at the Royal College of Art in London.

Data from the Heartsense monitor are sent to a cloud-based repository where they are analyzed with deep-learning algorithms that adapt and adjust to new data added to the knowledge base. The results are then sent back to the user, displayed on a smartphone app in near real-time. The company reports that tests of the Heartsense algorithms show they accurately detect more than 95 percent of atrial fibrillation incidents. The company also says using 3 monitoring points makes its device more accurate than similar wearable devices using only a single monitoring point.

Cambridge Heartware started up last year, founded by Cambridge information engineering professor Roberto Cipolla and cardiology clinical fellow Rameen Shakur, now at MIT. Initial funding for the company, located in Cambridge Science Park, is supporting 100 prototypes for testing as well as refining the A.I. algorithms. The company says clinical trials of Heartsense are underway in Lancashire, a county in northwest England.

Cambridge Heartware’s goal is to give cardiologists better data than currently available from Holter monitors. “Our aim was not to replace the cardiologist,” says Cipolla in a university statement, “but to give them diagnostic support in real time.” The following video shows data collected by the Heartsense device, as seen on the accompanying smartphone app.

More from Science & Enterprise:

*     *     *

Gilead Gains Genome-Editing Hepatitis B Therapy

Hepatitis-B virus

Hepatitis-B virus (CDC.gov, Pixnio)

13 September 2018. Biopharmaceutical company Gilead Sciences is acquiring a genome-editing technology for treating hepatitis-B, a viral disease affecting the liver. The deal is expected to bring Precision Biosciences in Durham, North Carolina, developer of the technology, at least $445 million if all parts of the agreement are fulfilled.

Hepatitis-B is a life-threatening viral infection of the liver, which if it becomes chronic, can cause cirrhosis — scarring of liver tissue — and liver cancer. The hepatitis-B virus is spread through blood or contact with other bodily fluids, such as from mother to child in pregnancy. World Health Organization says hepatitis-B is a global public health problem affecting some 257 million people now living with the disease and causing some 887,000 deaths in 2015. Another problem with hepatitis-B is there are few, if any, immediate symptoms of the disease, and it can go undetected for decades. While a vaccine is readily available to prevent hepatitis-B, there are now no complete cures.

Precision Biosciences offers a genome editing system called Arcus for medical and agricultural applications using its own synthetic enzymes. The company produces these synthetic enzymes, known as homing endonucleases to zero-in on specific DNA sequences, usually those with long strings of 12 to 40 base pairs that occur on rare occasions in the genome. The enzymes are small in size, says the company, making them precise editing tools, minimizing off-target breaks. Its homing endonucleases, says Precision, can also perform various editing tasks at the target site, including insertions and edits as well as deletions.

Gilead and Precision say current treatments suppress replication of the hepatitis-B virus, but do not clear the virus from the system. For the virus to replicate and advance the disease, the virus forms a closed circular DNA pattern, which Precision says can serve as the target for its genome-editing enzyme. The company says tests at Gilead’s lab show its genome-editing enzymes can target this circular DNA, including when integrated with human liver cells.

According to the agreement, Precision will be responsible for identification, development, and preclinical testing of enzymes for editing hepatitis-B viral DNA. While the deal does not have an upfront payment, Gilead will fund all research and development of these enzymes, and be responsible for clinical studies and commercialization. Precision will be eligible for milestone payments under the agreement totaling $445 million, as well as subsequent royalty payments on sales of products from the collaboration.

Gilead Sciences, in Foster City, California is developing biologic treatments for a wide range of disorders, including a treatment for the hepatitis-B virus, or HBV, currently in early-stage clinical trials as well as other liver diseases. Derek Jantz, Precision’s chief scientist, says in a joint statement, “Precision is pleased that initial studies with our Arcus platform have established an important role for genome editing in their HBV program. This is an excellent application for our technology, which has made notable progress toward therapeutic in vivo editing in relevant models over the last year.”

More from Science & Enterprise:

*     *     *

The Future of Health Care

– Contributed content –

Medical care

(Pexels.com)

13 September 2018. People who lament that the world is going in the wrong direction often overlook something crucially important: that health care is phenomenally advanced, and that advances in the sciences have made it possible to live longer and better than ever before. This is not an unimportant detail: the improvements in the health care sector over the past hundred years — which have been astronomical — have allowed the human population to grow from two billion to seven billion. Isn’t that incredible? And there’s more good news: the health care industry hasn’t finished yet. Indeed, the coming years will see things continue to progress. We take a look at some of the ways how below.

Integrating A.I. and robots

The robots are coming. For much of society, this might be a warning, as it means that somewhere in the region of 40% of jobs might be lost. But in the health care sector? The development of AI systems and robots are going to improve services, diagnoses, surgeries, errors, and more. They’re not going to replace doctors, since the “human contact” factor accounts for a big part of the overall health care experience, but instead will work in conjunction with the nurses and doctors, who will, in turn, be able to do a better job.

More efficient systems

The digital age has made everything more streamlined, but the thing that many people forget is that the “tech revolution” is still in its infancy. Soon, all spheres of business and health care will be sprinkled with digital efficiency, in turn making the services quicker, more reliable, and better for patients. There are companies who offer a doctor dispensing program, by which doctors are able to prescribe and dispense medication at the same time, saving the patient a trip for the pharmacy, and allowing them to begin treatment straight away. As things continue to progress, we’ll see more services being developed that makes life a little easy for sickly patients.

More diverse settings

The hospital will always be the hub for a community’s health care needs, but the fact is that many patients are unable to get to the hospital safely or at least without great difficulty. As the standard of mobile equipment improves, we’ll be able to see diagnosis and treatment taking place in more diverse settings, such as the home. This will be a tremendous service to the people who need on-going care but who can’t or don’t want to spend time in a hospital.

Better follow-up service

Follow-up services after treatment can be just as important as the treatment itself, but it’s just a fact that the system is slightly ineffective, if only because there’s a bigger gap between the patient and the provider. As technology is further integrated into health care, we’ll see patients able to conduct some of their follow up online, using a secure interface. If it’s determined that no-follow up is needed, then it’ll save the patient a trip to the hospital, the hospital an appointment, and the economy many save hours in lost working days.

*     *     *

Personalized Breast Cancer Trial Advances 7 Drugs

Laura Esserman

Laura Esserman at 12 September 2018 news conference (A. Kotok)

12 September 2018. A clinical trial with a design that allows for changes in its processes to meet the needs of individual patients says its results helped advance 7 new drugs for breast cancer into review by FDA. Leaders and participants in the I-SPY2 Trial described progress made by the study in a news conference today in Washington, D.C.

The I-SPY2 Trial — short for Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2 — aims to change the way clinical trials for breast cancer are designed and conducted, to focus more on improving patient outcomes and reduce the costs and time needed for randomized placebo-controlled clinical trials, considered the gold-standard for testing new therapies. The I-SPY program began in 2007, founded by Laura Esserman, professor of surgery and breast cancer specialist at University of California in San Francisco and biostatistics professor Donald Berry at MD Anderson Cancer Center in Houston. An earlier I-SPY1 trial tested the safety of proposed drugs, but also devised and refined processes for reducing time and cost of testing new drugs while enhancing patient outcome prospects.

The newer trial began in 2010, but now is running at 16 sites in the U.S., enrolling some 1,300 breast cancer patients. Spurring the need for a new type of trial, said Esserman at the news conference, was the urgency to find solutions for patients, “who don’t have the luxury of time while we get our act together.” I-SPY2 uses innovations to reduce time and resources for trials, such as a master protocol, where  a single trial design can be employed to test a series of precision-medicine treatments, with participating patients first screened for their biomarker profiles.

I-SPY2 employs biomarkers and MRI imaging to identify breast cancer patients with a high risk of disease recurrence, but also with the disease in its early stages, before it metastasizes, or spreads to other parts of the body. Catching the disease in its early stages, Esserman noted, allows for drugs that are less toxic than traditional chemotherapy and also provide for a greater likelihood of a complete response. The primary endpoint, or objective, of I-SPY2 is complete disappearance of the patients’ tumors before surgery, known as pathologic complete response, within 6 months from the start of treatment. At that point, the patient is evaluated for prospects of remaining cancer-free for 3 to 5 years.

Berry, co-principal investigator of I-SPY2 with Esserman, called the trial “a learning system,” where those interventions doing well are used more than treatments that are not working, rather than plowing ahead with the same drug with all participants. The trial employs an adaptive design with algorithms that make it possible to alter factors such as treatment regimens or sample sizes based on interim results. This approach seems particularly suited to precision medicine, where treatments are designed to meet the specific molecular profile of participants.

At the news conference, the I-SPY2 Trial received an endorsement from Janet Woodcock, director of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration. Woodcock said most clinical trials test a single intervention, measured by responses of average patients. She noted, however that with studies like I-SPY2, “We now have design and statistical tools to improve outcomes for all patients, not just the average patient.”

Esserman added that FDA is “out there championing the trial.” With FDA’s support, she said, I-SPY2 is now testing 19 drugs, with 7 of those drugs advanced to FDA review. Two of those therapies are receiving accelerated approval and one treatment is designated as a breakthrough therapy by FDA.

Vidya Balakrishna, a software company executive and participant in I-SPY2, told the news conference she was diagnosed with triple-negative breast cancer, where the tumors do not express hormonal or HER2 receptor proteins that are targets for most cancer drugs. In most cases, she said, this diagnosis means a poor prognosis and few treatment options that have not changed for 50 years. But after participation in I-SPY2, she is now cancer-free, and finally, “doesn’t think constantly about cancer.”

The I-SPY2 trial is sponsored by the Quantum Leap Healthcare Collaborative, a not-for-profit consortium of medical researchers and Silicon Valley entrepreneurs to improve clinical trial recruitment, conduct, and management.

More from Science & Enterprise:

*     *     *

Simple, Less Expensive Ultrasound Probe Developed

Polymer ultrasound team

Developers of polymer ultrasound device, L-R: Robert Rohling, Carolos Gerardo, and Edmond Cretu (Clare Kiernan, University of British Columbia)

12 September 2018. Engineers designed a device that sends and receives ultrasound signals with polymer plastics instead of silicon-based circuits, which can lower the cost of medical images. A team at University of British Columbia in Vancouver describes its device in yesterday’s issue of the journal Microsystems and Nanoengineering.

Researchers led Carlos Gerardo, a doctoral candidate in electrical and computer engineering at UBC, are seeking new methods for producing ultrasound images used in common devices for monitoring pregnancies and diagnosing heart disease, as well as other organs and blood flow inside the body. Ultrasound can be used non-invasively from outside the body and does not employ X-rays, which can be harmful. An ultrasound probe sends sound waves through the skin from a probe called a transducer, which then receives the signals that bounce back. A digital system collects and assembles the received signals and converts them to visual images, often in real time.

Transducer probes today are made from chips fabricated on silicon using piezoelectric crystals that generate electrical charges from mechanical stresses, in this case from sound waves, much like voice-recognition devices on smartphones. Gerardo, with UBC engineering professors Edmond Cretu and Robert Rohling developed an alternative transducer probe made from a type of polymer plastic. The plastic in this case is known as SU-8, a polymer used in microelectronics, which surrounds electrodes in a membrane. The polymer membranes react and vibrate, which are captured and transmitted through the electrodes.

To prove the concept, Gerardo and colleagues tested their device called polymer capacitive micro-machined ultrasound transducers, or polyCMUTs, in a tank of mineral oil as a simulated medium. The device, about the size of a band-aid, accurately captured images of 12 aluminum wires suspended in the oil. The researchers say the images produced by polyCMUTs are at least as sharp as those produced by today’s piezoelectric crystals.

A key advantage of polyCMUTs is their lower cost and simpler fabrication. “Transducer drums have typically been made out of rigid silicon materials that require costly, environment-controlled manufacturing processes, and this has hampered their use in ultrasound,” says Gerardo in a university statement. “By using polymer resin, we were able to produce polyCMUTs in fewer fabrication steps, using a minimum amount of equipment, resulting in significant cost savings.”

Cretu adds that their device’s lower power and flexible materials could make ultrasound more widely available. “Since our transducer needs just 10 volts to operate,” Cretu notes, “it can be powered by a smartphone, making it suitable for use in remote or low-power locations. And unlike rigid ultrasound probes, our transducer has the potential to be built into a flexible material that can be wrapped around the body for easier scanning and more detailed views, without dramatically increasing costs.”

The university filed for a patent on the technology. The researchers believe the costs for producing polyCMUTs can be reduced even further with production in a vacuum environment and using roll-to-roll manufacturing methods, enabling ultrasound to become a ubiquitous imaging process.

More from Science & Enterprise:

*     *     *

Car Insurance Myths You Need To Stop Believing

– Contributed content –

Car at night

(Pexels.com)

12 September 2018. Learning to drive is exciting for most people. There is nothing more thrilling than having your own freedom and your own set of wheels, being able to go where you want, when you want. However, if there is one thing that no one enjoys when it comes to owning a car, it is auto insurance. If you are looking for the perfect car insurance policy for you, read on to discover more about the auto insurance myths you need to stop believing.

Adding another driver will reduce your premiums – First and foremost, a lot of people believe that the best way to reduce the amount of premiums they pay is to simply add another driver. While this can sometimes work, it is not guaranteed. The term for this is ‘fronting’ and insurance companies have become wise to it, meaning that it is no longer as effective as it used to be. The best thing to do is try adding a driver, request a quote, and then remove the driver, request a quote, and compare the two.

If you get a ticket or you are involved in an accident, your insurance premiums will stay high forever – Fortunately, this is not the truth. In fact, there is a three-year limit. Once three years have passed, you can get a reduced rate again. If you are not happy with the rate has been presented to you by your current insurer, head to cheapautoinsurance.co to see if you can find a cheaper quote via another provider instead.

Black boxes have a curfew – A lot of people stay away from black boxes because they believe that they have a curfew, meaning they will only be able to drive during the day and not on the evening. While there were a few policies like this when black boxes first came onto the market, this is no longer the case. What black boxes take into account is your driving level, not the time of day you decide to get behind the wheel.

You can drive any vehicle if you have comprehensive cover – Last but not least, this is a myth that could result in you getting into a lot of trouble if you are not careful. A lot of people believe comprehensive cover means they can drive any car they wish. This is not true – it all depends on the specifics of the policy. Head to https://www.webuyanycar.com/guides/car-ownership/comprehensive-car-insurance/ for more information about what car insurance is and whether or not you need it.

As you can see, there are a number of different car insurance myths that people believe today. If you are guilty of believing any of the myths that have been mentioned above, there is no need to worry – most people are. At least you know the truth now. Hopefully, the information that has been provided above will put you in a better position when finding the right insurance policy for you.

Editor’s note: The opinions expressed in this post are the contributor’s and not those of Science & Enterprise.

*     *     *

Clinical Trial Testing Anti-Resistant Malaria Therapy

Malaria clinic

Malaria clinic in Mali (USAID.gov)

11 September 2018. A clinical trial is getting underway that tests the safety and dosage levels of a new drug to treat malaria and block resistance from developing to it. The drug, code-named DM1157, is made by DesignMedix Inc., a spin-off company from Portland State University in Oregon, where initial research on the drug was conducted.

Malaria, according to World Health Organization, affected 216 million people in 2016, which extracts heavy social and economic burdens in developing countries. In 2016, some 445,000 people died from malaria, of which 90 percent were in sub-Sahara Africa. Children under the age of 5 are particularly susceptible to the disease. The disease is caused by infections from the Plasmodium parasite transmitted by mosquitoes. In humans, the parasite multiplies in the liver, then infects red blood cells. Symptoms, including headache, fever, and vomiting, occur 10 to 15 days following transmission from a mosquito bite.

Chloroquine was an early and, until recent years, effective treatment for malaria, but the a number of parasite strains developed a resistance to chloroquine, making the drug ineffective in most parts of the world. DesignMedix licenses the research of David Peyton, a chemistry professor at Portland State, that founded the company in 2008, and where he continues as chief scientist. Peyton’s lab developed a technology that restores the potency of drugs against resistant pathogens, by designing hybrid forms of the old drugs with anti-resistant compounds bound to the original chemistry. The company applies the technology to create new drugs to treat infectious diseases where resistance develops to earlier therapies.

DM1157 is the company’s lead product, a modified form of chloroquine that builds in an agent interfering with Plasmodium’s metabolism like chloroquine, but also inhibits the parasite’s ability to expel the drug. National Institute of Allergy and Infectious Diseases, or NIAID, part of National Institutes of Health, supported the drug’s preclinical research and development through a Small Business Technology Transfer grant that continued through March 2018. Portland State received a U.S. patent for the technology applied to chloroquine-resistant malaria in November 2016, with Peyton listed as one of the two inventors.

“Existing malaria medicines are becoming less effective because of the rise in drug resistance in malaria parasites,” says Sandra Shotwell, DesignMedix’s co-founder and CEO in a joint university-company statement. “This new medicine is designed as a first line therapy to overcome drug resistance, and if approved could be used to treat millions of people worldwide, allowing many sickened with malaria to make a complete recovery.”

The early-stage clinical trial, sponsored by NIAID and conducted at Duke Clinical Research Institute in Durham, North Carolina, is recruiting 104 healthy participants to test the safety of DM1157 and its chemical activity in the body. Participants will be randomly divided into groups testing 7 dosage levels of DM1157, both single and multiple ascending dosage levels. Individuals in the trial will also be randomly assigned to fast before taking the drug or with food. The trial also includes participants assigned to receive a placebo.

The study team at Duke Clinical Research Institute is tracking participants’ vital signs like heart rate and temperature, as well as checking for irregular heart rhythms. Researchers are also watching for adverse effects and participants’ dropping out from the study. In addition, the team is measuring concentrations of DM1157 in the blood of participants and the time the drug stays in the blood stream before being cleared from the body.

More from Science & Enterprise:

*     *     *

Appeals Court Backs Broad Institute in Crispr Case

Crispr genome edits illustration

(NIH.gov)

11 September 2018. A U.S. appeals court supported the Broad Institute’s claims it invented a separate Crispr technology from University of California, affirming a previous U.S. patent office ruling. The decision yesterday by the the U.S. Court of Appeals for the Federal Circuit, the court established to hear intellectual property appeals, rejected arguments by University of California that discoveries at its Berkeley campus of Crispr genome editing using a Cas9 enzyme made it possible for the Broad Institute, to develop its Crispr-Cas9 applications.

Crispr, short for clustered regularly interspaced short palindromic repeats, is a technique for editing genomes based on bacterial defense mechanisms that use RNA to identify and monitor precise locations in DNA. The actual editing of genomes with Crispr in most cases today uses an enzyme known as Crispr-associated protein 9 or Cas9. RNA molecules guide the editing enzymes to specific genes needing repair, making it possible to address root causes of many diseases, but also adjust traits in plant crops by removing or changing specific genes.

Genome-editing discoveries spawned work on Crispr by many researchers, particularly those at the Broad Institute, a medical research center affiliated with Harvard University and MIT, led by geneticist Feng Zhang developing implementations they claimed were independent of studies by geneticists Jennifer Doudna at University of California in Berkeley and Emmanuelle Charpentier, the senior authors on the original paper describing the technique in 2012. Charpentier is now director of the Max Planck Institute for Infection Biology in Braunschweig, Germany.

As a result, Broad Institute filed its own U.S. patent for Crispr, leading to a challenge from University of California that said Broad interfered with its patent claims, meaning Broad took unfair advantage of California’s previous work. In response, Broad pointed out that Zhang’s work with Crispr focuses on eukaryotes, plant and animal cells where genetic material is found in the nucleus. The California research, in contrast, is conducted with prokaryotes, organisms without a cell nucleus, such as bacteria and other single-cell microorganisms. These differences, said Broad, call for different methods and techniques.

In February 2017, the Patent Trials and Appeal Board at the U.S. Patent and Trademark Office, or USPTO, found Broad Institute’s arguments more persuasive, and agreed that Broad’s technology would not have been an obvious derivative of University of California’s discoveries, ruling in effect that Broad Institute and University of California had distinct technologies, both eligible for patents. As reported by Science & Enterprise in June, USPTO went on to grant University of California a patent for its Crispr-Cas9 technology.

The appeals court yesterday reaffirmed the Patent Trials and Appeals Board decision. “We have considered UC’s remaining arguments and find them unpersuasive,” said the court. “We note that this case is about the scope of two sets of applied-for claims, and whether those claims are patentably distinct.” The court added that it did not rule on the validity of either claim.

In a statement yesterday, UC-Berkeley noted that “The decision thus does not preclude other proceedings, either in the U.S. Patent and Trademark Office or in the courts, by which UC may seek to establish that it is the actual inventor of use of the CRISP-Cas9 system in eukaryotic cells.” The university added that it’s evaluating further legal options in the courts or USPTO.

Since these cases were filed, Crispr technology has advanced with enhancements to improve its precision, as well as the discovery of drawbacks to Cas9 as an editing enzyme. Crispr is becoming widely commercialized, with licenses issued to spin-off enterprises from both UC-Berkeley and Broad Institute, and further licenses to other companies and labs developing a number of medical and agricultural applications.

More from Science & Enterprise:

*     *     *

Check Your Change – Tips to Give You a Healthier Bank Balance

– Contributed content –

Coin change jar

(Flickr)

11 September 2018. When you are trying to come up with ideas that will help you improve and make your finances better, there is a lot to think about. So many things have to happen in order to get into a position of financial security. There are a lot of things that play a part in the process of money management, and it’s something that so many people these days are bad at. The more you can do to keep on top of things, the better off you will be in the long run.

Think about the different elements involved in boosting your bank account, as well as how you can take action in this regard. Having a healthier bank balance is so important for the future, and you need to have some kind of financial security. These are some of the awesome things you can do to make sure you boost your bank account today.

Sell some junk

We all have junk lying around that is just gathering dust and not being used. Well, this is a potential goldmine for you as long as you use it effectively. There are a lot of things that will play a role in helping you improve your bank balance, but selling junk is perfect because it requires minimal effort, and has the added bonus of clearing space in the home as well.

Start your own business

Starting your own business is one of the best ways of bringing in more money and making your finances healthier. Of course, you are going to want a healthy and successful business in order to bring in the cash you need. This involves making sure you have the key skills to launch your business alone and ensure that it is launched effectively and successfully. If you can get this right, you are going to be well placed to make sure your business generates some good revenue.

Clear your debts ASAP

Clearing debt as quickly and efficiently as possible is so important, and this is something that can make a big difference to the way your finances feel. You might need help with this, so it’s a good idea to check out reviews by The Motley Fool, and check out how their Ascent program will help you make savings and clear debts in much better and more convenient ways.

Invest sensibly

Investing is something we would all love to be able to do well, but it can be so difficult to get it right sometimes. This is why you need to be sure you are focused on making the right investments for the future. Meet with a financial advisor and discuss this at length to make sure you make the right decisions for the future, and that your bank account thanks you in the long run.

There are a lot of things you need to keep in mind for the future, and it is important to think about what is affecting your money directly. If you can get this right, you should find yourself in a much better position financially, and there are a lot of things that will play a role in helping you save more and improve your financial situation.

Editor’s note: The opinions in this post are the contributor’s and not those of Science & Enterprise.

*     *     *